# US 2012/0252825 A1 · Beneficial effects of combination therapy on cholesterol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252825 A1
- Document ID: US20120252825A1
- Status: Published application
- Kind: A1
- Application number: 13/432,470
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: Pfizer Inc.
- Inventors: Keith Stuart Kanik; Samuel H. Zwillich; Mary Gardiner Boy
- Web page: https://patentgrep.com/patent/US20120252825A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses pharmaceutical combination therapies for the treatment or prevention of diseases in a mammal comprising a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the same and kits for achieving a therapeutic effect in a mammal comprising pharmaceutical combination therapies are further described.

## Claims

### Claim 1

A pharmaceutical combination therapy for the treatment or prevention of a disease in a mammal comprising:
a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof; and
a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The pharmaceutical combination therapy of claim 1, wherein the Janus Kinase inhibitor is a compound of the formula
or the pharmaceutically acceptable salt thereof; wherein
R1 is a group of the formula
wherein y is 0, 1 or 2;
R4 is selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkylsulfonyl, (C2-C6)alkenyl, (C2-C6)alkynyl wherein the alkyl, alkenyl and alkynyl groups are optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C1-C4)alkoxy, (C1-C6)acyloxy, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, cyano, nitro, (C2-C6)alkenyl, (C2-C6)alkynyl or (C1-C6)acylamino; or R4 is (C3-C10)cycloalkyl wherein the cycloalkyl group is optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C1-C6)acyloxy, (C1-C6)acylamino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, cyano, cyano(C1-C6)alkyl, trifluoromethyl(C1-C6)alkyl, nitro, nitro(C1-C6)alkyl or (C1-C6)acylamino;
R5 is (C2-C9)heterocycloalkyl wherein the heterocycloalkyl groups must be substituted by one to five carboxy, cyano, amino, deuterium, hydroxy, (C1-C6)alkyl, (C1-C6)alkoxy, halo, (C1-C6)acyl, (C1-C6)alkylamino, amino(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH, (C1-C6)alkylamino-CO—, (C2-C6)alkenyl, (C2-C6) alkynyl, (C1-C6)alkylamino, amino(C1-C6)alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)acyloxy(C1-C6)alkyl, nitro, cyano(C1-C6)alkyl, halo(C1-C6)alkyl, nitro(C1-C6)alkyl, trifluoromethyl, trifluoromethyl(C1-C6)alkyl, (C1-C6)acylamino, (C1-C6)acylamino(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)acylamino, amino(C1-C6)acyl, amino(C1-C6)acyl(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)acyl, ((C1-C6)alkyl)2amino(C1-C6)acyl, R15R16N—CO—O—, R15R16N—CO—(C1-C6)alkyl, (C1-C6)alkyl-S(O)m, R15R16NS(O)m, R15R16NS(O)m (C1-C6)alkyl, R15S(O)mR16N, R15S(O)mR16N(C1-C6)alkyl wherein m is 0, 1 or 2 and R15 and R16 are each independently selected from hydrogen or (C1-C6)alkyl; or a group of the formula
wherein a is 0, 1, 2, 3 or 4;
b, c, e, f and g are each independently 0 or 1;
d is 0, 1, 2, or 3;
X is S(O)n wherein n is 0, 1 or 2; oxygen, carbonyl or —C(═N-cyano)-;
Y is S(O)n wherein n is 0, 1 or 2; or carbonyl; and
Z is carbonyl, C(O)O—, C(O)NR— or S(O)n wherein n is 0, 1 or 2;
R6, R7, R8, R9, R10 and R11 are each independently selected from the group consisting of hydrogen or (C1-C6)alkyl optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C1-C6)acyloxy, (C1-C6)acylamino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, cyano, cyano(C1-C6)alkyl, trifluoromethyl(C1-C6)alkyl, nitro, nitro(C1-C6)alkyl or (C1-C6)acylamino;
R12 is carboxy, cyano, amino, oxo, deuterium, hydroxy, trifluoromethyl, (C1-C6)alkyl, trifluoromethyl(C1-C6)alkyl, (C1-C6)alkoxy, halo, (C1-C6)acyl, (C1-C6)alkylamino, ((C1-C6)alkyl)2 amino, amino(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH, (C1-C6)alkylamino-CO—, (C2-C6)alkenyl, (C2-C6) alkynyl, (C1-C6)alkylamino, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)acyloxy(C1-C6)alkyl, nitro, cyano(C1-C6)alkyl, halo(C1-C6)alkyl, nitro(C1-C6)alkyl, trifluoromethyl, trifluoromethyl(C1-C6)alkyl, (C1-C6)acylamino, (C1-C6)acylamino(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)acylamino, amino(C1-C6)acyl, amino(C1-C6)acyl(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)acyl, ((C1-C6)alkyl)2amino(C1-C6)acyl, R15R16N—CO—O—, R15R16N—CO—(C1-C6)alkyl, R15C(O)NH, R15OC(O)NH, R15NHC(O)NH, (C1-C6)alkyl-S(O)m, (C1-C6)alkyl-S(O)m—(C1-C6)alkyl, R15R16NS(O)m, R15R16NS(O)m (C1-C6)alkyl, R15S(O)mR16N, R15S(O)mR16N(C1-C6)alkyl wherein m is 0, 1 or 2 and R15 and R16 are each independently selected from hydrogen or (C1-C6)alkyl;
R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, amino, halo, hydroxy, nitro, carboxy, (C2-C6)alkenyl, (C2-C6)alkynyl, trifluoromethyl, trifluoromethoxy, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C10)cycloalkyl wherein the alkyl, alkoxy or cycloalkyl groups are optionally substituted by one to three groups selected from halo, hydroxy, carboxy, amino (C1-C6)alkylthio, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C5-C9)heteroaryl, (C2-C9)heterocycloalkyl, (C3-C9)cycloalkyl or (C6-C10)aryl; or R2 and R3 are each independently (C3-C10)cycloalkyl, (C3-C10)cycloalkoxy, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C6-C10)arylamino, (C1-C6)alkylthio, (C6-C10)arylthio, (C1-C6)alkylsulfinyl, (C6-C10)arylsulfinyl, (C1-C6)alkylsulfonyl, (C6-C10)arylsulfonyl, (C1-C6)acyl, (C1-C6)alkoxy-CO—NH—, (C1-C6)alkyamino-CO—, (C5-C9)heteroaryl, (C2-C9)heterocycloalkyl or (C6-C10)aryl wherein the heteroaryl, heterocycloalkyl and aryl groups are optionally substituted by one to three halo, (C1-C6)alkyl, (C1-C6)alkyl-CO—NH—, (C1-C6)alkoxy-CO—NH—, (C1-C6)alkyl-CO—NH—(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH—(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH—(C1-C6)alkoxy, carboxy, carboxy(C1-C6)alkyl, carboxy(C1-C6)alkoxy, benzyloxycarbonyl(C1-C6)alkoxy, (C1-C6)alkoxycarbonyl(C1-C6)alkoxy, (C6-C10)aryl, amino, amino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino, (C6-C10)aryl(C1-C6)alkoxycarbonylamino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, carboxy, carboxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH—, (C1-C6)alkyl-CO—NH—, cyano, (C5-C9)heterocycloalkyl, amino-CO—NH—, (C1-C6)alkylamino-CO—NH—, ((C1-C6)alkyl)2amino-CO—NH—, (C6-C10)arylamino-CO—NH—, (C5-C9)heteroarylamino-CO—NH—, (C1-C6)alkylamino-CO—NH—(C1-C6)alkyl, ((C1-C6)alkyl)2amino-CO—NH—(C1-C6)alkyl, (C6-C10)arylamino-CO—NH—(C1-C6)alkyl, (C5-C9)heteroarylamino-CO—NH—(C1-C6)alkyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C6-C10)arylsulfonyl, (C6-C10)arylsulfonylamino, (C6-C10)arylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C5-C9)heteroaryl or (C2-C9)heterocycloalkyl.

### Claim 3 (depends on 1)

The pharmaceutical combination therapy of claim 1, wherein the Janus Kinase inhibitor is selected from the group consisting of:
Methyl-[4-methyl-1-(propane-1-sulfonyl)-piperidin-3-yl]-(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)-amine;
4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carboxylic acid methyl ester;
3,3,3-Trifluoro-1-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-propan-1-one;
4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carboxylic acid dimethylamide;
({4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carbonyl}-amino)-acetic acid ethyl ester;
3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxopropionitrile;
3,3,3-Trifluoro-1-{4-methyl-3-[methyl-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-propan-1-one;
1-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-but-3-yn-1-one;
1-{3-[(5-Chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-methyl-amino]-4-methyl-piperidin-1-yl}-propan-1-one;
1-{3-[(5-Fluoro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-methyl-amino]-4-methyl-piperidin-1-yl}-propan-1-one;
N-cyano-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-N′-propylpiperidine-1-carboxamidine;
N-cyano-4,N′,N′-Trimethyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carboxamidine;
Methyl-[(3R,4R)-4-methyl-1-(propane-1-sulfonyl)-piperidin-3-yl]-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
(3R,4R)-)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carboxylic acid methyl ester;
3,3,3-Trifluoro-1-{(3RI4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-propan-1-one;
(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carboxylic acid dimethylamide;
{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carbonyl}-amino)-acetic acid ethyl ester;
3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile;
3,3,3-Trifluoro-1-{(3R,4R)-4-methyl-3-[methyl-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-propan-1-one;
1-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-but-3-yn-1-one;
1-{(3R,4R)-3-[(5-Chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-methyl-amino]-4-methylpiperid in-1-yl}-propan-1-one;
1-{(3R,4R)-3-[(5-Fluoro-7H-pyrrolo[2I3-d]pyrimidin-4-yl)-methyl-amino]-4-methyl-piperidin-1-yl}-propan-1-one;
(3R,4R)—N-Cyano-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-N′-propylpiperidine-1-carboxamidine; and
(3R,4R)—N-Cyano-4,N′,N′-Trimethyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carboxamidine,
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The pharmaceutical combination therapy of claim 1, wherein the Janus Kinase inhibitor is 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxopropionitrile or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The pharmaceutical combination therapy of claim 1, wherein the HMG-CoA reductase inhibitor is a statin.

### Claim 6 (depends on 5)

The pharmaceutical combination therapy of claim 5, wherein the statin is selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, cerivastatin, rivastatin, mevastatin, velostatin, compactin, dalvastatin, fluindostatin, rosuvastatin, pitivastatin, and dihydrocompactin.

### Claim 7 (depends on 5)

The pharmaceutical combination therapy of claim 5, wherein the statin is atorvastatin.

### Claim 8 (depends on 5)

The pharmaceutical combination therapy of claim 5, wherein the statin is atorvastatin calcium salt.

### Claim 9 (depends on 1)

The pharmaceutical combination therapy of claim 1, wherein the mammal is a human.

### Claim 10 (depends on 1)

The pharmaceutical combination therapy of claim 1, wherein the Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and the HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof are administered simultaneously, sequentially or separately.

### Claim 11 (depends on 1)

The pharmaceutical combination therapy of claim 1, wherein the ratio of Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof to the HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof is about 2:1 to about 1:40 w/w.

### Claim 12 (depends on 1)

The pharmaceutical combination therapy of claim 1, wherein the dosage form is selected from the group consisting of a solution, a suspension, a tablet, a pill, a sachet, a capsule, multiparticulates and a powder.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising:
a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof; and
a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof of claim 1; and
a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1, 13)

A method of treating a disease in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a Janus Kinase inhibitor and a HMG-CoA reductase inhibitor of claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of claim 13.

### Claim 15 (depends on 14)

The method of claim 14, wherein the disease is selected from the group consisting of atherosclerosis, myocardial infarction, hypocholesterolemia, hyperlipidemia, ischemic heart disease, congestive heart failure, acute coronary syndrome, plaque instability, coronary artery disease, cerebrovascular disease, peripheral vascular disease and cardiac risk management.

### Claim 16 (depends on 1, 13)

A method of inhibiting cholesterol biosynthesis in a mammal, comprising administering to a mammal in need thereof a Janus Kinase inhibitor and a HMG-CoA reductase inhibitor of claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of claim 13.

### Claim 17 (depends on 1, 13)

A method of lowering blood cholesterol level in a mammal, comprising administering to a mammal in need thereof a Janus Kinase inhibitor and a HMG-CoA reductase inhibitor of claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of claim 13.

### Claim 18

A kit for achieving a therapeutic effect in a mammal comprising:
a therapeutically effective amount of a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof; and
a therapeutically effective amount of a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof; and
a container.
